This rebound is physiological, driven by rapid hormone restoration rather than behavioral changes alone, and varies considerably between individuals
By weeks two through four, most patients start to see a warmer, more tanned appearance
Weight loss injections approved for chronic weight management in the US include semaglutide (Wegovy) and tirzepatide (Zepbound)
Both types of medications effectively lower blood glucose, but long-acting drugs may dominate the market due to higher patient compliance
Pushes Into Phase 3 With Strong Momentum Viking Therapeutics advanced its dual GLP-1/GIP agonist VK2735 into Phase 3 after achieving 14.7% weight loss without plateauing in Phase 2, positioning the program as a serious challenger in a rapidly expanding $150B obesity market
they also reduce the risk of cardiovascular disease, slow the progression of chronic kidney disease, and improve conditions like sleep apnea, said senior author David Kim, PhD, a health economist at UChicago